ChromaCode, Inc.

Attending PMWC - Precision Medicine World Conference? Don’t miss the presentation by our Chief Business Officer, Padma Sundar, who is speaking about using our cutting edge #HDPCR assay. ChromaCode’s unique ability to interrogate more than one target per color channel on digital PCR instruments enables applications that might otherwise require NGS. Featured example applications with fast turnaround time include (a) “rescue” assays for challenging samples (b) bespoke MRD assays and (c) donor-derived cell-free DNA testing of transplant patients. The presentation is part of PMWC’s Showcase Track S2: Clinical Dx/Tools Track. Learn more: https://lnkd.in/dEUqErYj #PMWC24 #dPCR #genomics #PMWCintl

In this story in Technology Networks originally by University of California, Davis, Blood tests for circulating tumor DNA have been shown to detect cancers up to 18 months before clinical diagnosis via CT scans. This method of early detection is pivotal for developing targeted therapies, aligning with ChromaCode's mission to revolutionize healthcare through accessible genomic technologies. For more, please visit: https://bit.ly/495d1Pd #HealthTech #HealthInnovation

🔬 Testing your genes for cancer risk is now more affordable, potentially saving lives. Innovation firms like ChromaCode, Inc. are spearheading efforts to democratize genetic screening, ensuring that individuals and families have access to crucial healthcare insights. This transformative approach, highlighted by NPR's Nell Greenfieldboyce, not only empowers individuals with knowledge about their genetics but also enables proactive measures for early detection and prevention. https://n.pr/45c2v7j #GeneticTesting #CancerAwareness #HealthcareInnovation

In the continuing series 'Conversations Life Science Leaders Aren't Having,' hear our Chairman & CEO Mark McDonough highlight ChromaCode, Inc.’s pivotal role in enhancing investor confidence.   #Biotech #Innovation #JPM2024 #Genomics

In case you missed it: In an insightful Q&A with Medical Device & Technology from last year, Mark McDonough, current Chairman & CEO of ChromaCode, Inc., delves into the revolutionary impact of HDPCR technology in genomics. McDonough highlights the technology's potential beyond lung cancer, including applications in transplant and tumor testing, and showcasing ChromaCode's commitment to advancing patient care through genomics. For more, read here: https://bit.ly/3IoqkPY #HealthTech #Genomics #Innovation

Tune into the latest MedTech Insight podcast from Citeline featuring Mark McDonough, Chairman & CEO of ChromaCode, Inc., as he shares valuable insights into the future of genomic solutions. Mark discusses the transformative potential of their technology, upcoming regulatory challenges, and what 2024 holds for the diagnostics industry. An enlightening listen for those interested in the cutting-edge of healthcare innovation. To access the podcast episode, please visit: https://bit.ly/4bZ7ZXj #HealthcareInnovation #Cancer

First in Human, a podcast by Vial, features Mark McDonough, Chairman & CEO of ChromaCode discussing the transformative potential of HDPCR technology in early detection of disease. Mark shares insights into his professional journey—from military service to leading innovation in the genomics field. Discover how ChromaCode is overcoming industry challenges to introduce groundbreaking technologies, aiming to improve patient outcomes through faster, comprehensive genomic solutions. To read the transcript or download the podcast episode, visit: https://bit.ly/4376O43 To listen to the episode on YouTube, please visit: https://bit.ly/42XBQeI #HealthcareInnovation #Genomics #Leadership

Watch Mark McDonough, Chairman and CEO of ChromaCode, Inc. engage in another insightful discussion with Jeff Harmon of 'Conversations Life Science Leaders Aren't Having' and Russo Partners, on growth discipline in today’s challenging environment. #Biotech #Innovation #JPM2024 #Genomics